Drug Pricing

Commentary

Congress Eyes Regulating Drug Ads, It Won’t Mean Lower Prices

“Knowing what something costs before buying it is just common sense.” That’s how Sen. Chuck Grassley, R-Iowa, justified a bill he introduced in January to require drug companies to include a medicine’s list price in their advertisements. Unfortunately, his Drug-price Transparency for Consumers, or DTC, Act — co-sponsored by Sen. ...
Commentary

The World’s Medicine Chest

Just released from PRI – read The World’s Medicine Chest, the latest book from PRI President, CEO and Thomas W. Smith Fellow in Health Care Policy. The World’s Medicine Chest explores how America became the world’s leader in biopharmaceutical innovation through market capitalism. Click here to register to watch a special live ...
Commentary

Insulin prices are falling due to market forces — no price caps required

California State Sen. Scott Wiener, D-San Francisco, recently introduced legislation that would cap cost-sharing for insulin at $35 a month, regardless of whether a patient has public or private insurance. It’s a popular idea. But it may not be necessary. The cost of insulin has been falling due to market ...
Commentary

Patients Pay Dearly for Biden’s Pricing Mess

On Jan. 17, just days before leaving office, the Biden administration announced the next 15 prescription drugs dispensed through Medicare Part D that will be subject to price controls on Jan. 1, 2027, under the terms of the Inflation Reduction Act. Among them is the blockbuster semaglutide, a prescription medication ...
Commentary

Creative Counting Can’t Fix The Inflation Reduction Act’s Flaws

Just three days before President Biden left office, his appointees tried to tie incoming Trump staffers’ hands on a health policy decision that affects millions of Americans and tens of billions in federal spending. On January 17, the Centers for Medicare & Medicaid Services announced a new list of 15 ...
Commentary

California could lead the way on bipartisan prescription drug reform

California State Senator Scott Wiener, D-San Francisco, recently introduced a bill aimed at reining in pharmacy benefit managers (PBMs), the middlemen largely responsible for the dysfunction plaguing our nation’s prescription drug market. Wiener’s effort should attract the support of lawmakers on both the left and right. By cracking down on ...
Commentary

The Dangers Hidden In CMS’ Drug Pricing Regulation

CMS recently announced the next 15 drugs that will be subject to price negotiations under the Inflation Reduction Act of 2022 (IRA). These are negotiations in name only because CMS can levy penalties on any manufacturer that fails to comply with the process. Since the penalties include an excise tax ...
Blog

Read about a last minute Biden administration plan the Trump administration should undo

CMS’ Drug Price Controls Have Expanded to the Next 15 Medicare Part D Drugs

For every complex problem there is an answer that is clear, simple, and wrong. H.L. Mencken Back in 2022, the Biden Administration reasoned that drug costs are too high and devised a clear and simple answer: incorporate a Maximum Fair Price (MFP) provision into the Inflation Reduction Act of 2022 ...
Drug Innovation

PRI Responds to CMS Adding 15 Additional Drugs That Will Be Subjected to Government Price Controls

PRI’s scholars responded to today’s action by the Centers for Medicare & Medicaid (CMS) announcing 15 additional drugs under Medicare Part D that will be subject to government price setting effective January 1, 2027.  The action was authorized by the Inflation Reduction Act signed by President Biden in August 2022. ...
Biosimilars

The Biosimilar Promise

Reforms Can Improve Competition and Generate More Savings

Reforms Can Improve Competition and Generate More Savings By Wayne Winegarden  | January 7, 2025 READ PDF Executive Summary Reforms that will strengthen the biosimilar market and expand savings opportunities include: Reforming (ideally repealing) the Inflation Reduction Act’s price control measures. Improving the incentives underlying the current buy-and-bill system to ...
Commentary

Congress Eyes Regulating Drug Ads, It Won’t Mean Lower Prices

“Knowing what something costs before buying it is just common sense.” That’s how Sen. Chuck Grassley, R-Iowa, justified a bill he introduced in January to require drug companies to include a medicine’s list price in their advertisements. Unfortunately, his Drug-price Transparency for Consumers, or DTC, Act — co-sponsored by Sen. ...
Commentary

The World’s Medicine Chest

Just released from PRI – read The World’s Medicine Chest, the latest book from PRI President, CEO and Thomas W. Smith Fellow in Health Care Policy. The World’s Medicine Chest explores how America became the world’s leader in biopharmaceutical innovation through market capitalism. Click here to register to watch a special live ...
Commentary

Insulin prices are falling due to market forces — no price caps required

California State Sen. Scott Wiener, D-San Francisco, recently introduced legislation that would cap cost-sharing for insulin at $35 a month, regardless of whether a patient has public or private insurance. It’s a popular idea. But it may not be necessary. The cost of insulin has been falling due to market ...
Commentary

Patients Pay Dearly for Biden’s Pricing Mess

On Jan. 17, just days before leaving office, the Biden administration announced the next 15 prescription drugs dispensed through Medicare Part D that will be subject to price controls on Jan. 1, 2027, under the terms of the Inflation Reduction Act. Among them is the blockbuster semaglutide, a prescription medication ...
Commentary

Creative Counting Can’t Fix The Inflation Reduction Act’s Flaws

Just three days before President Biden left office, his appointees tried to tie incoming Trump staffers’ hands on a health policy decision that affects millions of Americans and tens of billions in federal spending. On January 17, the Centers for Medicare & Medicaid Services announced a new list of 15 ...
Commentary

California could lead the way on bipartisan prescription drug reform

California State Senator Scott Wiener, D-San Francisco, recently introduced a bill aimed at reining in pharmacy benefit managers (PBMs), the middlemen largely responsible for the dysfunction plaguing our nation’s prescription drug market. Wiener’s effort should attract the support of lawmakers on both the left and right. By cracking down on ...
Commentary

The Dangers Hidden In CMS’ Drug Pricing Regulation

CMS recently announced the next 15 drugs that will be subject to price negotiations under the Inflation Reduction Act of 2022 (IRA). These are negotiations in name only because CMS can levy penalties on any manufacturer that fails to comply with the process. Since the penalties include an excise tax ...
Blog

Read about a last minute Biden administration plan the Trump administration should undo

CMS’ Drug Price Controls Have Expanded to the Next 15 Medicare Part D Drugs

For every complex problem there is an answer that is clear, simple, and wrong. H.L. Mencken Back in 2022, the Biden Administration reasoned that drug costs are too high and devised a clear and simple answer: incorporate a Maximum Fair Price (MFP) provision into the Inflation Reduction Act of 2022 ...
Drug Innovation

PRI Responds to CMS Adding 15 Additional Drugs That Will Be Subjected to Government Price Controls

PRI’s scholars responded to today’s action by the Centers for Medicare & Medicaid (CMS) announcing 15 additional drugs under Medicare Part D that will be subject to government price setting effective January 1, 2027.  The action was authorized by the Inflation Reduction Act signed by President Biden in August 2022. ...
Biosimilars

The Biosimilar Promise

Reforms Can Improve Competition and Generate More Savings

Reforms Can Improve Competition and Generate More Savings By Wayne Winegarden  | January 7, 2025 READ PDF Executive Summary Reforms that will strengthen the biosimilar market and expand savings opportunities include: Reforming (ideally repealing) the Inflation Reduction Act’s price control measures. Improving the incentives underlying the current buy-and-bill system to ...
Scroll to Top